Among high‐confidence pathogenic PTEN mutations in endometrial cancers, the proportion with POLE consensus mutational signature scores of >0 was substantially and significantly greater among POLE‐mutant cases than among MMR‐P and MMR‐D tumours [10 of 14 (71.4%) versus 14 of 82 (17.1%) mutations, respectively; p = 7.8 × 10–3, Fisher's exact test]. This evidence concerns the gene PTEN and neoplasm.